WORKINGGROUP 2
- Participants:
ParticipantOrganizationE-mailPhone numberFaxDr. Axel Cloeckhart INRA, France axel.cloeckaert@tours.inra.fr / / Dr. Bernd Appel / b.appel@bfr.bund.de / / Dr. Constantinos Sakarellos Univeristy of Ioannina, Ioannina, Greece ksakarel@cc.uoi.gr / / Dr. Louis Moreno UCL, Brussels, Belgium moreno@dice.ucl.ac.be / / Dr. Maria Nica Dr Victor Babes Hospital for Infectious/Tropical Diseases and Dr. Victor Babes Foundation, Bucharest centru@cdt-babes.ro / iuliana_a@yahoo.com 0040 21 31 79 503 0040 21 31 79 502 Dr. Maria Sakarellos-Daitsiotis The Laboratory of Peptide Chemistry, Department of Chemistry, University of Ioannina, Ioannina, Gree msakarel@cc.uoi.gr 0030 65 19 83 90 0030 65 14 58 40 Dr. Natascha Helena Beyer / Dr. Niels Heegaard The Statens Serum Institute, Copenhagen, Denmark nat@ssi.dk 0045 32 68 32 68 0045 32 68 38 68 Dr. Patricia Renesto The Unite des Rickettsies CNRS UMR 6020 - IFR 48 - Faculte de Medecine, Marseille, France patricia.renesto@medecine.univ-mrs.fr 0033 49 13 24 625 0033 49 13 87 772 Dr. Sevil Din?er Yildiz Technical University, Faculty of Chemistry-Metallurgy, Istanbul, Turkey sevild77@gmail.com 0090 21 24 49 17 78 0090 21 24 49 15 60 Prof. Dr. Claude P. Muller, Chair The Institute of Immunology, Laboratoire National de Sant?, Luxembourg claude.muller@LNS.ETAT.LU 00352 49 06 04 00352 49 06 86
- Description:
WG2 Antigenicity.
- Objective:
Preparation of antibodies against relevant biological targets including microorganisms, biotoxins and proteins. This will allow full characterization of the microorganisms antigenic properties. - Description:
This work package will bring together experts in the field of antigenicity, diagnostics and prophylaxis. Polyclonal antibodies, specific antibody fragments from phage display libraries, and mainly monoclonal antibodies (MAbs) will be developed/produced for a rapid, specific, sensitive and differentiating detection of bacteria, viruses and fungi, and bacterial and fungal toxins. Antibodies will be produced against bacteria, viruses and fungi, and derived products that fall within the scope of the project. In virology, special attention will be put on related microorganisms from the human and veterinary fields, with a special emphasis on poxviridae and BSL4 viruses. In addition, antibodies will be generated against peptides, proteins, glycoproteins, and protein-conjugated glycooligo- and polymers. This will allow the full antigenic properties of the microorganisms to be defined, which may also lead to a better understanding of the immunological reactions in infections.
Antibodies will be produced against the biological targets using classical polyclonal antibody production in rabbits, classical hybridoma technology for the production of MAbs, and new technology for the production of specific antibody fragments by phage display libraries. The latter methodology is also called antibody engineering technology and is a new area in the field of molecular immunology for production of libraries of Fab fragments by bacterial expression of the genes coding for the VH and the VL domain and display of fragments on the surface of filamentous phage. Such phage display methodology permits a rapid construction of large combinatorial antibody libraries. The antibody genes can be recovered from lymphocytes mRNA by RT-PCR and then cloned.
- Objective:
- Actions:
ActionDescriptiondownload
-
Publications:


